In the Phase I study of BMS-986453, what efficacy was observed in BCMA- and GPRC5D-naive patients treated at dose levels 1 and 2?
Overall response rate of 100%, complete response or better in 88%, and 100% MRD negativity
Overall response rate of 83%, complete response or better in 57%, and 50% MRD negativity
Overall response rate of 74%, complete response or better in 19%, with MRD negativity not assessed